PCM
AGN

Prelude Capital Management’s Allergan plc AGN Stock Holding History

Prelude Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,800
Closed -$319K – 2386
2020
Q1 		$319K Sell
1,800
-13,100
-88% -$2.47M 0.02% 371
2019
Q4 		$2.85M Buy
14,900
+200
+1% +$36.1K 0.11% 128
2019
Q3 		$2.47M Buy
14,700
+13,500
+1,125% +$2.2M 0.11% 146
2019
Q2 		$201K Buy
+1,200
New +$166K 0.01% 732
2015
Q4 		– Sell
-3,800
Closed -$1.03M – 1792
2015
Q3 		$1.03M Buy
+3,800
New +$1.17M 0.15% 164

Other funds holding AGN

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
C
Cerebellum San Francisco, California $21.5M AUM
B
Barings Charlotte, North Carolina $5.64B AUM 18.33% 1-Year Est. Return
JJ
JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Prelude Capital Management's AGN Position: Q2 2020 in Review

Prelude Capital Management sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 90,626 shares — an estimated $16.1M sold.

Prelude Capital Management first reported a position in AGN in Q1 2014 and held it in 24 quarters. The position peaked at $34.5M in Q3 2019. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

  • Prelude Capital Management reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
  • Prelude Capital Management sold 90,626 Allergan plc shares in Q2 2020, an estimated $16.1M.
  • Prelude Capital Management first reported a position in Allergan plc in Q1 2014 and held it in 24 quarters.
  • Prelude Capital Management's Allergan plc position peaked at $34.5M in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.